Letters to HCPs

Important information for Healthcare Professionals

Esmya (UPA) 5mg - UK DHPC 23.03.2020

This is a DHPC letter as approved by EMA and MHRA following EMA’s Pharmacovigilance Risk Assessment Committee (PRAC)’s suggestion to suspend Esmya 5mg tablets (ulipristal acetate) during the ongoing Article 31 safety review.

For Healthcare Professionals